Tranexamic Acid Dosing Frequency for Bleeding
For trauma-related bleeding, administer tranexamic acid as a 1 g IV bolus over 10 minutes as soon as possible (ideally within 90 minutes, but no later than 3 hours post-injury), followed by a second 1 g dose if bleeding continues after 30 minutes or restarts within 24 hours.
Context-Specific Dosing Regimens
Trauma and Major Hemorrhage
The European trauma guidelines 1 and recent evidence 2 support early administration of 1 g IV over 10 minutes, followed by 1 g infusion over 8 hours for patients with hemorrhagic shock or significant bleeding. However, emerging data 3 demonstrates that single bolus dosing (1-2 g) achieves equivalent outcomes to bolus-plus-infusion regimens with similar mortality (21% across all groups) and thromboembolic risk.
Critical timing considerations:
- Benefit decreases by 10% for every 15-minute delay 4
- No benefit after 3 hours; potentially harmful beyond this window 4
- The 90-minute window is more critical than pre-hospital vs. in-hospital administration 2
Practical approach for trauma:
- 1-2 g IV bolus (15-30 mg/kg) as single dose for patients in hemorrhagic shock 2
- Consider second 1 g dose if bleeding persists after 30 minutes 4
- Avoid doses >4 g due to marked increase in thromboembolic risk (HR 5.33) 2
Post-Partum Hemorrhage
WHO guidelines 4 provide the most definitive dosing:
- 1 g IV (100 mg/mL) at 1 mL/min over 10 minutes immediately upon diagnosis
- Second 1 g dose if bleeding continues after 30 minutes OR restarts within 24 hours
- Must be given within 3 hours of birth
- Applies to all PPH regardless of cause (trauma, atony, etc.)
Hemophilia-Related Bleeding (Dental Procedures)
FDA-approved dosing 5:
- Before extraction: 10 mg/kg IV single dose immediately before procedure
- After extraction: 10 mg/kg IV 3-4 times daily for 2-8 days
- Infuse no faster than 1 mL/minute to avoid hypotension 5
Renal dosing adjustments required 5:
- Serum Cr 1.36-2.83 mg/dL: 10 mg/kg twice daily
- Serum Cr 2.83-5.66 mg/dL: 10 mg/kg once daily
- Serum Cr >5.66 mg/dL: 10 mg/kg every 48 hours OR 5 mg/kg every 24 hours
Gastrointestinal Bleeding
Do NOT use tranexamic acid for GI bleeding. The HALT-IT trial 6 demonstrated no mortality benefit (3.7% vs 3.8%, RR 0.99) with increased venous thromboembolism risk (0.8% vs 0.4%, RR 1.85) and seizures (0.6% vs 0.4%, RR 1.73). This is not cost-effective and results in worse outcomes 6.
Key Safety Considerations
Absolute contraindications 5:
- Active intravascular clotting
- Subarachnoid hemorrhage (risk of cerebral edema/infarction)
- Known hypersensitivity to TXA
Route verification critical 5:
- FOR INTRAVENOUS USE ONLY - intrathecal administration causes seizures and cardiac arrhythmias
- Label syringes clearly with IV route
- Dose-dependent; marked increase at ≥4 g
- Avoid in patients without shock (absolute risk difference -5% to +5% for mortality, but +4% for thromboembolism)
- Avoid concomitant Factor IX concentrates, hormonal contraceptives 5
Seizure risk 5:
- Dose-dependent, particularly >2 g
- Monitor for myoclonic movements, twitching
- Consider EEG monitoring in high-risk patients
- Discontinue if seizures occur
Clinical Decision Algorithm
Identify bleeding type and timing:
- Trauma <3 hours → Use TXA
- PPH <3 hours from birth → Use TXA
- GI bleeding → Do NOT use TXA
- Hemophilia dental procedure → Use TXA per protocol
Assess for contraindications:
- Active clotting, subarachnoid hemorrhage, hypersensitivity → Do NOT use
Determine shock status:
- Hemorrhagic shock present → 1-2 g bolus immediately
- No shock → Risk-benefit less favorable; consider withholding
Administer appropriate dose:
- Single bolus preferred over bolus-plus-infusion for simplicity 3
- Repeat dose only if bleeding persists/recurs per context-specific guidelines
Monitor for complications:
- Thromboembolism, seizures, hypotension during infusion